Our Patroon Creek office has reopened. Use lower lot entrance for all appointments. Albany Medical Center patients should continue to use upper lot entrance to check in for appointments in Suite 210. Radiation, PET and CT patients use radiation entrance in lower lot.Learn More
Make First Appointment Refer a Patient

Clinical Trials & Research

Home / Clinical Trials & Research / View Open Trials

View Open Trials

Anal
Bladder
Breast
Gastric
Head and Neck
Lung (Non Small Cell)
Lymphomas
Melanoma
Myelomas
Other
Prostate
Solid Tumors

Anal

  • Ph2 INCMGA00012 mSCAC

    A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

Bladder

  • NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Sitravatinib + Nivo Adv/Met Urothelial

    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)

  • Ph2 enfortumab (ASG-22CE) Urothelial

    A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • INCB054828 Urothelial FGF/FGFR

    A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • RdDbBlnd NivovsPlbo HighRiskMI Urothl

    A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma- Bristol-Myers Squibb CA209-274

Breast

  • FLEX Registry: Evaluate New Gene Express

    MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Ph1/2 Ibrutinib+Tras HER2 amp/MBC

    Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  • Ph1/2 Ibrutinib+Tras HER2 amp/MBC

    Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  • Ph 3 Tesetaxel+Capecitabine mHER2-

    A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

  • Cape/tras +/- ONT-380 HER2+ mBC

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206)

Gastric

  • Ph3 BLU-285 vs Regorafenib GIST

    An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Head and Neck

  • Ph3 Atezo SCC H&N

    A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH RISK LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (WO40242)

Lung (Non Small Cell)

  • Ph3 ALK+ mNSCLC (Brigatinib-3001)

    Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Ph2 Brigatinib ALK+ NSCLC (TAK2002)

    Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Ph2 Poziotinib EGFR/HER2 NSCLC

    A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

  • Ph3 Adj canakinumab NSCLC

    A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

  • VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC

    Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)

  • Ph3 Nivo vs Plat-Doublet chemo NSCLC

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

  • BSC +/- LAN in Lung NETs [SPINET]

    USO 15079 A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs. Placebo plus BSC for Tumor Control in Subjects with Well-Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors (Spinet) - Ipsen A-US-52030-328

Lymphomas

Melanoma

Myelomas

  • Ph1/2 INCB001158 + SC Dara vs Dara SC MM

    A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma (INCB 01158-206)

Other

  • Ph2 Itacitinib +/- Ruxo in MF

    An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Prostate

  • Abirat+pred +/- abemaciclib mCRPC

    A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM

  • Ph2 Nivo mCRPC (CheckMate 9KD)

    A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)

  • Rucaparib v PhysC mCRPC (TRITON3)

    TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

Solid Tumors

  • Ph2 Anti-PD1 Cisplatin Solids

    INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)